<i>KRAS</i> overexpression independent of <i>RAS</i> mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia

Jing‐dong Zhou, Dong‐ming Yao, Xixi Li, Ting‐juan Zhang, Wei Zhang, Ji‐chun Ma, Hong Guo, Zhaoqun Deng, Jiang Lin, Jun Qian

Oncotarget · 2017 · 34 citations · 29 references

DOIFull text

Open access

Concepts

Abstract

// Jing-Dong Zhou 1, 3, * , Dong-Ming Yao 2, 3, * , Xi-Xi Li 1, 3, * , Ting-Juan Zhang 1, 3 , Wei Zhang 1, 3 , Ji-Chun Ma 2, 3 , Hong Guo 2, 3 , Zhao-Qun Deng 2, 3 , Jiang Lin 2, 3 and Jun Qian 1, 3 1 Department of Hematology, Affiliated People&rsquo;s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People&rsquo;s Republic of China 2 Laboratory Center, Affiliated People&rsquo;s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People&rsquo;s Republic of China 3 The Key Laboratory of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People&rsquo;s Republic of China * These authors have contributed equally to this work Correspondence to: Jun Qian, email: qianjun0007@hotmail.com Jiang Lin, email: linjiangmail@sina.com Keywords: RAS , expression, mutation, prognosis, acute myeloid leukemia Received: April 25, 2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accepted: June 29, 2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Published: August 02, 2017 ABSTRACT The prognostic value of RAS mutations has been systematically investigated in acute myeloid leukemia (AML). However, clinical significance of RAS expressions in AML remains poorly determined. To explore the clinical significance, we analyzed KRAS and NRAS expressions in 143 de novo AML patients by real-time quantitative PCR. KRAS and NRAS expressions were significantly up-regulated in AML patients. KRAS and NRAS mutations were identified in 4% (6/143) and 8% (12/143) of these patients, respectively. However, no significant association was observed between RAS mutations and expressions. High KRAS expression was associated with older age, higher white blood cells, and a tendency of higher platelets, whereas high NRAS expression was only correlated with older age. Complete remission (CR) rate and overall survival of AML patients were adversely affected by KRAS overexpression, but not NRAS overexpression. Multivariate analysis revealed that KRAS acted as an independent prognostic predictor in cytogenetically normal AML (CN-AML). Moreover, the prognostic value of KRAS expression was validated using the published data from Gene Expression Omnibus datasets. In the follow-up patients, KRAS expression rather than NRAS expression in CR time tended to decrease compared to newly diagnosis time, and both KRAS and NRAS expressions were significantly increased when in relapse time. Our findings revealed that RAS overexpression and mutations were common events in AML with potential therapeutic target value. KRAS overexpression independent of RAS mutations conferred an adverse prognosis in CN-AML.

References

29